• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 23, 2018

View Archived Issues

Allergan CRL in fibroids a boon for Abbvie following another elagolix phase III success

Abbvie Inc. trumped Allergan plc in the effort to treat women with abnormal bleeding due to uterine fibroids. Abbvie, of North Chicago, reported top-line data from the phase III ELARIS UF-EXTEND extension study, which showed that, at 12 months, elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg/norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding, with 87.9 percent of women with uterine fibroids achieving clinical response. Read More

Argenx shares rise as Abbvie doubles down on GARP accord

DUBLIN – Argenx SE passed a critical milestone in its immuno-oncology alliance with Abbvie Inc., by delivering an IND package for ARGX-115, its first-in-class antibody directed at glycoprotein A repetitions predominant (GARP), a cell-surface docking receptor that modulates the activity of the immunosuppressive cytokine transforming growth factor beta (TGF-beta). Abbvie, of North Chicago, has now exercised an option on the program, in which it originally obtained an interest two and a half years ago. (See BioWorld Today, April 22, 2016.) Read More

Compass charts path to large-scale psilocybin depression test

Psilocybin, the psychoactive core of magic mushrooms, could be headed toward late-stage trials in treatment-resistant depression (TRD), pending the results of a soon-to-start phase IIb study. London-based Compass Pathways Ltd. has received permission from the FDA and additional regulators to run a dose-ranging study in up to 216 patients across Europe and North America. The trial, which seeks to enroll 216 patients at 12 to 15 research sites, will begin in the U.K. later this month and is expected to read out toward the end of 2019. Read More

Requiring PROs for Medicare coverage puts CAR T before the horse, MEDCAC told

Given the potential diversity of CAR T therapies and the ongoing evolution of patient-reported outcome (PRO) tools, Medicare should not require the use of PROs in making coverage determinations for new gene therapies, several experts told the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Wednesday. Read More

Jounce trounced but faith not misplaced; continuing bid may turn story around

Ahead of June's American Society of Clinical Oncology (ASCO) meeting in Chicago, an abstract related to the data to be unveiled by Jounce Therapeutics Inc. so alarmed Wall Street that the company's shares lost 35 percent of their value, and the situation worsened when the data rolled out. But there may be cause to maintain hope for JTX-2011, the agonist of inducible T-cell co-stimulator (ICOS), a protein on the surface of certain T cells that Jounce believes can stimulate an immune response against solid tumors. Read More

Appointments and advancements

Hikma Pharmaceuticals USA Inc., of Eatontown, N.J., a subsidiary of London-based Hikma Pharmaceuticals plc, appointed Kristy Ronco executive vice president, sales and marketing for its generics division. Read More

Other news to note

Neuren Pharmaceuticals Ltd., of Melbourne, Australia, received the initial payment of $10 million from Acadia Pharmaceuticals Inc., of San Diego, as part of their licensing agreement for Neuren's Rett syndrome and Fragile X syndrome treatment, trofinetide. (See BioWorld, Aug. 8, 2018.) Read More

Financings

Ampliphi Biosciences Corp., of San Diego, has filed to raise up to $12 million from the sale of shares of its common stock. It also intends to grant the underwriters a 30-day option to purchase additional shares. The offering has not yet been priced. The company is focused on the the development of targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections. Read More

Clinical data for Aug. 22, 2018

Read More

Regulatory actions for Aug. 22 , 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe